Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BCMs), will present preclinical data demonstrating that a BCM-derived biologic can deliver steady-state plasma concentrations of a bispecific T cell engager at clinically relevant doses for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). Findings from the study, conducted jointly with researchers at Seattle Children’s Research Institute, will be presented during the Society for Immunotherapy of Cancer’s 38th Annual Meeting.
